Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurovance unveils three clinical trials to support advanced development of centanafadine
The series of three trials include a phase 1 imaging study, a phase 2 efficacy trial in adult ADHD and a phase 1 pharmacokinetics (PK) study evaluating several
The series of three trials include a phase 1 imaging study, a phase 2 efficacy trial in adult ADHD and a phase 1 pharmacokinetics (PK) study evaluating several
The alliance seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers. Kymouse – Kymab’s human antibody discovery platform – has unparalleled diversity
CEP-9722 is a novel, orally active, small molecule selective inhibitor of PARP-1 and PARP-2 enzymes that will be developed by Checkpoint as both a monotherapy and in combination
The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with VIEKIRA PAK for 12 weeks. The FDA grants priority review designation to
The clinical trial is currently enrolling patients at multiple centers in Australia and New Zealand. MONARCH is intended to identify one or more combinations of ARC-520 and other
The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity. As per the terms of the agreement, Jubilant
NCCN, a not-for-profit alliance of 26 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency
In February 2015, the company licensed exclusive, worldwide rights in its adenosine receptor antagonist programme for use in all therapeutic applications to Corvus, a U.S.-based biotechnology company. At
Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel
The formal authorizations from regulatory agencies in France, Italy and Czech Republic, and the positive opinions from national ethic committees in these three countries enable the initiation of